Beyond one and done: engineering durable, redosable cell‑based gene therapies

“The one‑and‑done mantra has real appeal – the idea of curing someone with a single administration is compelling. But it demands perfection, and perfection is extraordinarily difficult to achieve.”

Abi Pinchbeck, Editor, Cell & Gene Therapy Insights , speaks with Chris Hopkins, Co‑founder and CEO, Glafabra Therapeutics, Utah, UT, USA, about redoseable cell‑based gene therapy, a platform spanning Fabry, Pompe, and Gaucher diseases, and what durable, if not permanent, treatment could mean for patients.

Please enter your email to access content Read now